Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia

Intensive Care Medicine

Volumn 29, Issue 11, 2003, Pages 2072-2076

  Wood, G Christopher ^a   Hanes, Scott D ^a   Boucher, Bradley A ^a   Croce, Martin A ^a   Fabian, Timothy C ^a  

^a Univ of TN College of Medicine   (United States)

Author keywords

Acinetobacter baumannii; Critical illness; Doxycycline; Minocycline; Pneumonia

Indexed keywords

DOXYCYCLINE; MINOCYCLINE; TETRACYCLINE;

ACINETOBACTER BAUMANNII; ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; DISEASE ASSOCIATION; HUMAN; INJURY; PNEUMONIA; TREATMENT OUTCOME; UNITED STATES; VENTILATOR;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; APACHE; BRONCHOALVEOLAR LAVAGE FLUID; CRITICAL CARE; CRITICAL ILLNESS; CROSS INFECTION; DOXYCYCLINE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INFECTION CONTROL; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; PNEUMONIA, BACTERIAL; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; TENNESSEE; TRAUMA CENTERS; TREATMENT OUTCOME;

EID: 0344394201     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-003-1811-2     Document Type: Article

References (20)

1. American Thoracic Society (1995) Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. A consensus statement. Am J Respir Crit Care Med 153:1711-1725
2. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J (2001) Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: Geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999). Clin Infect Dis 32(Suppl ii): 104-113
3. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA (2002) Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 34:1425-1430
4. Rodríguez-Hernández MJ, Pachón J, Pichardo C, Cuberos L, Ibánez-Martínez J, García-Curiel A, Caballero FJ, Moreno I, Jiménez-Mejías ME (2000) Imipenem, doxycycline and amikacin in monotherapy in combination in Acinetobacter baumannii experimental pneumonia. J Antimicrob Chemother 45:493-501
5. Croce MA, Fabian TC, Waddle-Smith L, Melton SM, Minard G, Kudsk KA, Pritchard FE (1998) Utility of Gram's stain and efficacy of quantitative cultures for posttraumatic pneumonia: A prospective study. Ann Surg 227:743-755
6. Leibovici L, Paul M, Poznanski O, Drucker M, Samra Z, Konigsburger H, Pitlik SD (1997) Monotherapy versus lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 41:1127-1133
7. DuPont H, Carbon C, Carlet J (2000) Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. Antimicrob Agents Chemother 44:2028-2033
8. Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D, Chopart P, Schaad U, Herter C, Eggimann P, Huber O, Ricou B, Suter P, Auckenthaler R, Chiolero R, Bille J, Scheidegger C, Frei R, Glauser MP (1994) Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 38:1309-1313
9. Croce MA, Fabian TC, Stewart RM, Pritchard FE, Minard G, Trenthem L, Kudsk KA (1993) Empiric monotherapy versus combination therapy of nosocomial pneumonia in trauma patients. J Trauma 35:303-311
10. Urban C, Go E, Mariano N, Berger BJ, Avraham I, Rubin D, Rahal JJ (1993) Effect of sulbactam on infection caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 167:448-451
11. Jiménez-Mejías ME, Pachón J, Becerril B, Palomino-Nicas J, Rodriguez-Cobacho A, Revuelta M (1997) Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/ sulbactam. Clin Infect Dis 24:932-935
12. Cisneros JM, Reyes MJ, Pachón J, Becerril B, Caballero FJ, Garcia-Garmendia JL, Ortiz C, Cobacho AR (1996) Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 22:1026-1032
13. Jellison TK, McKinnon PS, Rybak MJ (2001) Epidemiology, resistance, and outcomes of Acinetobacter baumannii bactermia treated with imipenemcilastatin or ampicillin-sulbactam. Pharmacotherapy 21:142-148
14. Corbella X, Ariza J, Ardanuy C, Vuelta M, Tabau F, Sora M, Pujol M, Gudiol F (1998) Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 42:793-8026
15. Jiménez-Mejías ME, Becerril B, Márquez-Rivas FJ, Pichardo C, Cuberos L, Pachon J (2000) Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with intravenous colistin sulfomethate sodium. Eur J Clin Microbiol Inf Dis 19:970-971
16. Wood CA, Reboli AC (1993) Infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 168:1602-1603
17. Levin AS, Barone AA, Penço J, Santos MV, Marinho IS, Arruda EA, Manrique EI, Costa SF (1999) Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 28:1008-1011
18. Fernandez-Viladrich P, Corbella X, Corral F, Tubau F, Mateu A (1999) Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin Infect Dis 28:916-917
19. Wood GC, Boucher BA (2000) Aerosolized antimicrobial therapy in acutely ill patients. Pharmacotherapy 20:166-181
20. Wolff M, Joly-Guillou ML, Farinotti R, Carbon C (1999) In vivo efficacies of combinations of -lactams, -lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob Agents Chemother 43:1406-1411